---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-028771"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:08:34.154316+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q2 2022 revenue rises to $46M, net loss widens to $7M; 4 new program starts

## Summary
- Total revenue $45.9M, up 66% from $27.6M in Q2 2021; royalties from bebtelovimab contributed $33.2M.
- Net loss $6.8M ($0.02/share) vs loss $2.3M ($0.01/share) in prior year, driven by higher R&D and G&A investments.
- Added 4 program starts in Q2, cumulative 88 (+47% YoY); total programs under contract 164 (+19% YoY).
- Six molecules cumulatively advanced to clinic, up from 4 at Q2 2021.
- Cash & marketable securities $1.022B; R&D expenses $26.7M (+78% YoY).

## SEC filing metadata
- accession: 0001564590-22-028771
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459022028771/0001564590-22-028771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459022028771/abcl-8k_20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-028771
- JSON: https://secwatch.observer/filing/0001564590-22-028771.json
- Plain text: https://secwatch.observer/filing/0001564590-22-028771.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.